Among adverse events of special interest (AESIs), a heightened focus may be required on sarcoidosis (RR = 8.96 [95% CI 0.48–166.13]), hypopituitarism (RR = 6.04 [95% CI 0.73–49.99]), increases in ALT (RR = 4.58 [95% CI 2.50–8.39]) or AST (RR = 4.00 [95% CI 2.17–7.38]), autoimmune hepatitis (RR = 3.99 [95% CI 0.45–35.51]), and colitis (RR = 3.78 [95% CI 2.47–5.80]). This evidence concerns the gene GPT and colitis.